Difficulty: Medium
Average Score: 66%
Practice
Systemic corticosteroids are rarely indicated in the treatment of atopic dermatitis because
Correct answer
B
Rationale
In the treatment of atopic dermatitis in pediatric patients, systemic corticosteroids are rarely indicated due to the risk of rebound flare after therapy discontinuation. This is the correct answer because using systemic corticosteroids can lead to temporary improvement of symptoms, but once discontinued, there is a high likelihood of the condition worsening, often more aggressively than before, necessitating further treatment.
Option A, toxic side effects after long-term use, is not the primary reason systemic corticosteroids are avoided in atopic dermatitis. While long-term use can indeed lead to adverse effects, the risk of rebound flare upon discontinuation is more concerning in this context.
Option C, stating that systemic corticosteroids cannot do more than what topical treatments can, is incorrect. Systemic corticosteroids are potent anti-inflammatory agents and can provide rapid and significant relief, but their long-term use in atopic dermatitis is limited due to the risk of rebound flares.
Option D, tapering being required even after short-term use, is a common practice with systemic corticosteroids to prevent withdrawal symptoms and adrenal suppression. While this is important to consider, it is not the primary reason why systemic corticosteroids are rarely indicated in the treatment of atopic dermatitis in pediatric patients.
Educationally, it is crucial for healthcare providers to understand the implications of using systemic corticosteroids in pediatric patients with atopic dermatitis. Emphasizing the risks of rebound flare and the importance of exploring alternative treatments, such as topical corticosteroids, emollients, and immunomodulators, can help optimize patient care and outcomes while minimizing potential adverse effects associated with systemic treatments.
Option A, toxic side effects after long-term use, is not the primary reason systemic corticosteroids are avoided in atopic dermatitis. While long-term use can indeed lead to adverse effects, the risk of rebound flare upon discontinuation is more concerning in this context.
Option C, stating that systemic corticosteroids cannot do more than what topical treatments can, is incorrect. Systemic corticosteroids are potent anti-inflammatory agents and can provide rapid and significant relief, but their long-term use in atopic dermatitis is limited due to the risk of rebound flares.
Option D, tapering being required even after short-term use, is a common practice with systemic corticosteroids to prevent withdrawal symptoms and adrenal suppression. While this is important to consider, it is not the primary reason why systemic corticosteroids are rarely indicated in the treatment of atopic dermatitis in pediatric patients.
Educationally, it is crucial for healthcare providers to understand the implications of using systemic corticosteroids in pediatric patients with atopic dermatitis. Emphasizing the risks of rebound flare and the importance of exploring alternative treatments, such as topical corticosteroids, emollients, and immunomodulators, can help optimize patient care and outcomes while minimizing potential adverse effects associated with systemic treatments.